S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
NASDAQ:MRKR

Marker Therapeutics Stock Forecast, Price & News

$1.78
0.00 (0.00 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.75
$1.81
50-Day Range
$1.68
$2.36
52-Week Range
$1.32
$3.77
Volume386,179 shs
Average Volume1.88 million shs
Market Capitalization$147.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
30 days | 90 days | 365 days | Advanced Chart
Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Marker Therapeutics logo

About Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.04 out of 5 stars

Medical Sector

513th out of 1,351 stocks

Pharmaceutical Preparations Industry

251st out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Marker Therapeutics (NASDAQ:MRKR) Frequently Asked Questions

Is Marker Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Marker Therapeutics stock.
View analyst ratings for Marker Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Marker Therapeutics?

Wall Street analysts have given Marker Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marker Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Marker Therapeutics' next earnings date?

Marker Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Marker Therapeutics
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01.
View Marker Therapeutics' earnings history
.

How has Marker Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Marker Therapeutics' stock was trading at $1.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRKR stock has decreased by 10.1% and is now trading at $1.78.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MRKR?

3 analysts have issued 12-month target prices for Marker Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Marker Therapeutics' stock price to reach $6.67 in the next year. This suggests a possible upside of 274.5% from the stock's current price.
View analysts' price targets for Marker Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Marker Therapeutics' key executives?

Marker Therapeutics' management team includes the following people:
  • Peter L. Hoang, President, Chief Executive Officer & Director
  • Anthony H. Kim, Chief Financial Officer
  • Ann M. Leen, Chief Scientific Officer
  • Mythili Koneru, Chief Medical Officer
  • Gerald Garrett, Vice President-Clinical Operations

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Millennium Management LLC (1.64%), Victory Capital Management Inc. (1.16%), Kennedy Capital Management Inc. (0.72%), Geode Capital Management LLC (0.69%) and Renaissance Technologies LLC (0.48%). Company insiders that own Marker Therapeutics stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends for Marker Therapeutics
.

Which major investors are selling Marker Therapeutics stock?

MRKR stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., State Street Corp, Northern Trust Corp, Citadel Advisors LLC, Susquehanna International Group LLP, Victory Capital Management Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Marker Therapeutics
or view top insider-selling stocks.

Which major investors are buying Marker Therapeutics stock?

MRKR stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace LLP, AR Asset Management Inc., Vanguard Group Inc., Ergoteles LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Marker Therapeutics stock in the last two years include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker, and Peter L Hoang.
View insider buying and selling activity for Marker Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Marker Therapeutics?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $1.78.

How much money does Marker Therapeutics make?

Marker Therapeutics has a market capitalization of $147.88 million and generates $470,000.00 in revenue each year. The company earns $-28,710,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Marker Therapeutics have?

Marker Therapeutics employs 44 workers across the globe.

What is Marker Therapeutics' official website?

The official website for Marker Therapeutics is www.markertherapeutics.com.

Where are Marker Therapeutics' headquarters?

Marker Therapeutics is headquartered at 3200 Southwest Freeway Suite 2240, Houston TX, 77027.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at (713) 400-6400 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.